{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:13:19Z","timestamp":1772496799294,"version":"3.50.1"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0230526","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T17:33:10Z","timestamp":1584552790000},"page":"e0230526","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":37,"title":["Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin\u2019s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5282-6571","authenticated-orcid":true,"given":"Astri Fjelde","family":"Maaland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"Saidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Torgue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Heyerdahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania A. Rozgaja","family":"Stallons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jostein","family":"Dahle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,3,18]]},"reference":[{"key":"pone.0230526.ref001","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program Cancer Stat Facts\u2014Chronic Lymphocytic Leukemia seer.cancer.gov2019 Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html"},{"key":"pone.0230526.ref002","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program Cancer Stat Facts\u2014Non-Hodkin Lymphoma seer.cancer.gov2019 Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html"},{"issue":"24","key":"pone.0230526.ref003","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib Resistance in Chronic Lymphocytic Leukemia","volume":"370","author":"RR Furman","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"pone.0230526.ref004","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab resistance","volume":"24","author":"AR Rezvani","year":"2011","journal-title":"Best practice & research Clinical haematology"},{"issue":"1","key":"pone.0230526.ref005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"CD Herling","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"pone.0230526.ref006","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1\u20132 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"D Tan","year":"2013","journal-title":"Blood"},{"issue":"10091","key":"pone.0230526.ref007","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"JO Armitage","year":"2017","journal-title":"The Lancet"},{"issue":"11","key":"pone.0230526.ref008","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s00259-019-04417-1","article-title":"Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003","volume":"46","author":"AF Maaland","year":"2019","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"1","key":"pone.0230526.ref009","first-page":"85","article-title":"Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma","volume":"33","author":"J Dahle","year":"2013","journal-title":"Anticancer Res"},{"key":"pone.0230526.ref010","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/leu.2014.32","article-title":"The CD37-targeted antibody\u2013drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model","volume":"28","author":"KA Beckwith","year":"2014","journal-title":"Leukemia"},{"issue":"20","key":"pone.0230526.ref011","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2013-05-505685","article-title":"A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies","volume":"122","author":"J Deckert","year":"2013","journal-title":"Blood"},{"issue":"15","key":"pone.0230526.ref012","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1182\/blood-2011-04-351932","article-title":"A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies","volume":"118","author":"K-H Heider","year":"2011","journal-title":"Blood"},{"issue":"Suppl 1","key":"pone.0230526.ref013","article-title":"LYMRIT 37\u201301: A Phase I\/II Study of 177lu-Lilotomab Satetraxetan (Betalutin\u00ae) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL)\u2014Analysis with 6-Month Follow-up","volume":"132","author":"A Kolstad","year":"2018","journal-title":"Blood"},{"issue":"1","key":"pone.0230526.ref014","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17010033","article-title":"Targeted Radionuclide Therapy of Human Tumors","volume":"17","author":"SV Gudkov","year":"2016","journal-title":"International Journal of Molecular Sciences"},{"key":"pone.0230526.ref015","first-page":"6148357","article-title":"In Vivo Radionuclide Generators for Diagnostics and Therapy","author":"PE Edem","year":"2016","journal-title":"Bioinorganic Chemistry and Applications"},{"issue":"2","key":"pone.0230526.ref016","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0090-8258(89)80040-X","article-title":"The effect of the \u03b1-emitting radionuclide lead-212 on human ovarian carcinoma: A potential new form of therapy","volume":"32","author":"J Rotmensch","year":"1989","journal-title":"Gynecologic Oncology"},{"issue":"12","key":"pone.0230526.ref017","first-page":"1944","article-title":"Radioimmunotherapy targeting of HER2\/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1","volume":"38","author":"E Horak","year":"1997","journal-title":"Journal of Nuclear Medicine"},{"issue":"5","key":"pone.0230526.ref018","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/cbr.2005.20.557","article-title":"alpha-particle radioimmunotherapy of disseminated peritoneal disease using a Pb-212-labeled radioimmunoconjugate targeting HER2","volume":"20","author":"DE Milenic","year":"2005","journal-title":"Cancer Biotherapy and Radiopharmaceuticals"},{"issue":"7","key":"pone.0230526.ref019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069613","article-title":"Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using Pb-212","volume":"8","author":"V Boudousq","year":"2013","journal-title":"Plos One"},{"issue":"1","key":"pone.0230526.ref020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4161\/19420862.2014.985160","article-title":"Evaluation of cetuximab as a candidate for targeted alpha-particle radiation therapy of HER1-positive disseminated intraperitoneal disease","volume":"7","author":"DE Milenic","year":"2015","journal-title":"mAbs"},{"key":"pone.0230526.ref021","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.nucmedbio.2017.01.003","article-title":"B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models","volume":"47","author":"BB Kasten","year":"2017","journal-title":"Nucl Med Biol"},{"issue":"4","key":"pone.0230526.ref022","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.tranon.2017.04.004","article-title":"Targeted alpha-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab","volume":"10","author":"DE Milenic","year":"2017","journal-title":"Translational Oncology"},{"key":"pone.0230526.ref023","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nucmedbio.2017.12.004","article-title":"Pb-212-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models","volume":"58","author":"BB Kasten","year":"2018","journal-title":"Nuclear Medicine and Biology"},{"issue":"4","key":"pone.0230526.ref024","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19040925","article-title":"Pb-212-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models","volume":"19","author":"BB Kasten","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"issue":"15","key":"pone.0230526.ref025","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1158\/1078-0432.CCR-05-0619","article-title":"Melanoma therapy via peptide-targeted alpha-radiation","volume":"11","author":"YB Miao","year":"2005","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"pone.0230526.ref026","first-page":"1881","article-title":"Significant systemic therapeutic effects of high-LET immunoradiation by (212)pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice","volume":"40","author":"ZQ Tan","year":"2012","journal-title":"International Journal of Oncology"},{"issue":"7","key":"pone.0230526.ref027","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.nucmedbio.2005.06.009","article-title":"Pretargeted radioimmunotherapy in tumored mice using an in vivo Pb-212\/Bi-212 generator","volume":"32","author":"FM Su","year":"2005","journal-title":"Nuclear Medicine and Biology"},{"issue":"12","key":"pone.0230526.ref028","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1021\/acs.bioconjchem.7b00612","article-title":"Metal-Free Cycloaddition Chemistry Driven Pretargeted Radioimmunotherapy Using alpha-Particle Radiation","volume":"28","author":"MA Shah","year":"2017","journal-title":"Bioconjugate Chemistry"},{"issue":"7","key":"pone.0230526.ref029","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/COC.0000000000000353","article-title":"Safety and Outcome Measures of First-in-Human Intraperitoneal alpha Radioimmunotherapy With 212Pb-TCMC-Trastuzumab","volume":"41","author":"RF Meredith","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"51","key":"pone.0230526.ref030","doi-asserted-by":"crossref","first-page":"9995","DOI":"10.1002\/anie.201004243","article-title":"Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase","volume":"49","author":"S Jeger","year":"2010","journal-title":"Angew Chem Int Ed Engl"},{"issue":"3","key":"pone.0230526.ref031","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1021\/bc400574z","article-title":"Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates","volume":"25","author":"P Dennler","year":"2014","journal-title":"Bioconjug Chem"},{"issue":"1","key":"pone.0230526.ref032","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s002620050456","article-title":"Rapid blood clearance of mouse IgG2a and human IgG1 in many nude and nu\/+ mouse strains is due to low IgG2a serum concentrations","volume":"46","author":"N Reddy","year":"1998","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"5","key":"pone.0230526.ref033","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","article-title":"Affinity of human IgG subclasses to mouse Fc gamma receptors","volume":"9","author":"G Dekkers","year":"2017","journal-title":"mAbs"},{"issue":"7","key":"pone.0230526.ref034","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.4049\/jimmunol.1200356","article-title":"Crosstalk between human IgG isotypes and murine effector cells","volume":"189","author":"MB Overdijk","year":"2012","journal-title":"J Immunol"},{"issue":"6292","key":"pone.0230526.ref035","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/347479a0","article-title":"The scid mutation in mice causes a general defect in DNA repair","volume":"347","author":"GM Fulop","year":"1990","journal-title":"Nature"},{"issue":"Suppl 5","key":"pone.0230526.ref036","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"B Eichhorst","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"pone.0230526.ref037","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10967-012-2243-7","article-title":"Biodistribution of Pb-212 conjugated trastuzumab in mice","volume":"296","author":"NR Schneider","year":"2013","journal-title":"Journal of Radioanalytical and Nuclear Chemistry"},{"key":"pone.0230526.ref038","article-title":"Effect of Gender on the Radiation Sensitivity of Murine Blood Cells","author":"Billings","year":"2015","journal-title":"Gravit Space Res"},{"issue":"6","key":"pone.0230526.ref039","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3892\/mmr.2014.2089","article-title":"Effect of gender differences on the regulation of renal ischemia-reperfusion-induced inflammation in mice","volume":"9","author":"KP Kang","year":"2014","journal-title":"Molecular medicine reports"},{"issue":"4","key":"pone.0230526.ref040","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239","article-title":"Targeted \u03b1 particle immunotherapy for myeloid leukemia","volume":"100","author":"JG Jurcic","year":"2002","journal-title":"Blood"},{"issue":"21","key":"pone.0230526.ref041","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1158\/1078-0432.CCR-10-0382","article-title":"Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia","volume":"16","author":"TL Rosenblat","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"22","key":"pone.0230526.ref042","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4050.4050","article-title":"Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (Ac-225)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)","volume":"128","author":"JG Jurcic","year":"2016","journal-title":"Blood"},{"key":"pone.0230526.ref043","first-page":"132","article-title":"A Phase 2 Study of Actinium-225 (Ac-225)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)\u2014Interim Analysis of 1.5 mu ci\/Kg\/Dose","author":"EL Atallah","year":"2018","journal-title":"Blood"},{"issue":"10","key":"pone.0230526.ref044","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/PL00000229","article-title":"Differences in normal values for murine white blood cell counts and other hematological parameters based on sampling site","volume":"50","author":"JA Nemzek","year":"2001","journal-title":"Inflamm Res"},{"issue":"1","key":"pone.0230526.ref045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1524\/ract.1993.60.1.1","article-title":"The Chemical Fate of 212Bi-DOTA Formed by \u03b2- Decay of 212Pb(DOTA)2-","volume":"60","author":"S Mirzadeh","year":"1993","journal-title":"Radiochimica Acta"},{"issue":"6","key":"pone.0230526.ref046","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/cbr.2009.0628","article-title":"Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice","volume":"24","author":"T Back","year":"2009","journal-title":"Cancer Biother Radiopharm"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0230526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T17:33:35Z","timestamp":1584552815000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0230526"}},"subtitle":[],"editor":[{"given":"Jonathan","family":"Engle","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,3,18]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0230526","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,18]]}}}